Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Next Previous
Trial Profile

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abatacept (Primary) ; Busulfan (Primary) ; Busulfan (Primary) ; Cyclophosphamide (Primary) ; Filgrastim (Primary) ; Fludarabine (Primary) ; Fosphenytoin (Primary) ; Granulocyte colony-stimulating factors (Primary) ; Immune globulin (Primary) ; Levetiracetam (Primary) ; Lorazepam (Primary) ; Melphalan (Primary) ; Mycophenolate mofetil (Primary) ; Mycophenolate mofetil (Primary) ; Palifermin (Primary) ; Posaconazole (Primary) ; Ruxolitinib (Primary) ; Tacrolimus (Primary) ; Tacrolimus (Primary) ; Tocilizumab (Primary) ; Voriconazole (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Acronyms ACCELERATE

Most Recent Events

  • 29 Jul 2025 Planned initiation date changed from 1 Jun 2025 to 1 Jul 2025.
  • 29 Jul 2025 Status changed from not yet recruiting to recruiting.
  • 11 Mar 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top